Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pegasys/Copegus combo pack clears FDA

Executive Summary

Roche will continue to sell Pegasys (peginterferon alpha-2a) and Copegus (ribavirin) separately following FDA's June 4 approval of a co-packaged version. Roche is not announcing a launch date or pricing information for the combination. Availability of a co-packaged product could lessen the likelihood that patients will combine Pegasys with generic equivalents to Schering-Plough's Rebetol (ribavirin) (1"The Pink Sheet" April 12, 2004, p. 38)...

You may also be interested in...



Ribavirin ANDAs Clear FDA; Schering Goes Generic Too

Three Rivers/Par, Sandoz and Schering-Plough are launching their ribavirin generics at a 10% discount to Schering's Rebetol

Boehringer Ingelheim, Gubra Enter Third Obesity Deal

The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.

First Phase III Data For Inovio's Immunotherapy VGX-3100 Encouraging In Cervical Dysplasia

Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel